Oseltamivir acid hydrochloride
Based on 76 publication(s) in Google Scholar
Oseltamivir acid hydrochloride is an active metabolite of the antiviral agent Oseltamivir (HY-13317) ethylester. Oseltamivir acid hydrochloride belongs to baseline toxicants in toxicity ratio analysis.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 1415963-60-8
- Formula: C14H25ClN2O4
- Molecular Weight:320.81
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Oseltamivir acid hydrochloride
More- Nature. 2023 Jun;618(7965):590-597. [Abstract]
- Nat Commun. 2026 Feb 19. [Abstract]
- Nat Commun. 2025 Jul 23;16(1):6771. [Abstract]
- ACS Nano. 2014 Jun 24;8(6):5468-77. [Abstract]
- Sci Transl Med. 2026 Feb 18;18(837):eadt3889. [Abstract]
- Small. 2020 May;16(20):e2000556. [Abstract]
- J Environ Manage. 2015 Oct 1:162:326-33. [Abstract]
- Arch Pharm Res. 2018 Jun;41(6):664-676. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]
- J Ethnopharmacol. 2025 Jun 12:349:119964. [Abstract]
- J Ethnopharmacol. 2025 Feb 10;338(Pt 2):119091. [Abstract]
- Talanta. 2025 Oct 2;298(Pt B):128948. [Abstract]
- Eur J Med Chem. 2023 Dec 5:261:115845. [Abstract]
- Eur J Med Chem. 2021 Oct 5:221:113567. [Abstract]
- Eur J Med Chem. 2020 Aug 15:200:112423. [Abstract]
- Eur J Med Chem. 2017 Dec 1:141:648-656. [Abstract]
- Anal Chim Acta. 2025 Nov 8:1374:344522. [Abstract]
- Int J Mol Sci. 2019 Dec 12;20(24):6261. [Abstract]
- BMC Microbiol. 2025 May 15;25(1):292. [Abstract]
- Eur J Pharm Sci. 2020 Jan 15:142:105143. [Abstract]
- Molecules. 2019 Jun 10;24(11):2176. [Abstract]
- Eur J Pharm Sci. 2018 Jan 1:111:167-176. [Abstract]
- Molecules. 2017 Nov 18;22(11):1998. [Abstract]
- Molecules. 2016 Aug 26;21(9):1133. [Abstract]
- Eur J Pharm Sci. 2015 Oct 12:78:47-53. [Abstract]
- Sci Rep. 2024 Nov 16;14(1):28287. [Abstract]
- Virol Sin. 2021 Jun;36(3):490-500. [Abstract]
- RSC Med Chem. 2020 Jan 22;11(1):148-154. [Abstract]
- Antiviral Res. 2025 Aug:240:106209. [Abstract]
- Antiviral Res. 2025 Jul:239:106174. [Abstract]
- Antiviral Res. 2024 Sep:229:105959. [Abstract]
- Antiviral Res. 2022 Jun;202:105325. [Abstract]
- Antiviral Res. 2020 Oct:182:104886. [Abstract]
- Antiviral Res. 2020 Apr;176:104751. [Abstract]
- Antiviral Res. 2017 Jul:143:106-112. [Abstract]
- Antiviral Res. 2016 May:129:81-92. [Abstract]
- Antiviral Res. 2016 Mar:127:68-78. [Abstract]
- Antiviral Res. 2014 Nov:111:69-77. [Abstract]
- Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. [Abstract]
- Antimicrob Agents Chemother. 2015 Aug;59(8):4962-73. [Abstract]
- J Infect Dis. 2024 Jun 14;229(6):1830-1835. [Abstract]
- Virol J. 2025 Jun 4;22(1):181. [Abstract]
- Virol J. 2018 May 21;15(1):88. [Abstract]
- Influenza Other Respir Viruses. 2025 Oct;19(10):e70176. [Abstract]
- Viruses. 2024 Sep 14;16(9):1467. [Abstract]
- Viruses. 2021 Aug 11;13(8):1590. [Abstract]
- Viruses. 2020 Mar 19;12(3):337. [Abstract]
- J Med Virol. 2023 Jul;95(7):e28968. [Abstract]
- J Med Virol. 2021 Jun;93(6):3455-3464. [Abstract]
- Separations. 2026 Apr;13(4):105.
- Peptides. 2019 Feb:112:14-22. [Abstract]
- Animal Model Exp Med. 2025 Jan 26. [Abstract]
- SLAS Discov. 2024 Jan;29(1):66-76. [Abstract]
- PLoS One. 2016 May 27;11(5):e0156400. [Abstract]
- PLoS One. 2014 Oct 21;9(10):e110631. [Abstract]
- FEBS Open Bio. 2013 Oct 29:3:484-9. [Abstract]
- Virology. 2025 Oct:611:110642. [Abstract]
- Virology. 2020 Jun:545:1-9. [Abstract]
- J Nat Med. 2019 Jun;73(3):487-496. [Abstract]
- Arch Virol. 2024 May 28;169(6):130. [Abstract]
- Arch Virol. 2014 Dec;159(12):3269-78. [Abstract]
- Biomed Chromatogr. 2021 Apr;35(4):e5024. [Abstract]
- Biosci Biotechnol Biochem. 2020 Apr;84(4):774-779. [Abstract]
- bioRxiv. 2026 Jun 10.
- bioRxiv. 2025 Nov 2.
- Res Sq. 2025 Feb 04.
- bioRxiv. 2024 May 8:2024.05.06.592815. [Abstract]
- bioRxiv. 2023 Aug 12.
- bioRxiv. 2020 Mar.
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
- bioRxiv. July 26, 2018.
- Biomed Pharmacother. 2018 Jan:97:385-394. [Abstract]
- Biomed Pharmacother. 2017 Sep:93:636-645. [Abstract]
- Oncotarget. 2017 Sep 15;8(47):83142-83154. [Abstract]
- Evid Based Complement Alternat Med. 2015:2015:917670. [Abstract]
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
IF
-
Cell Proliferation/Viability Assay
Biological Activity
Chemical Information
-
CAS No. 1415963-60-8
-
Appearance Solid
-
Molecular Weight 320.81
-
Formula C14H25ClN2O4
-
Color White to light brown
-
SMILES
O=C(O)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC.Cl
-
Synonyms
GS 4071 hydrochloride; Ro 64-0802 hydrochloride; Oseltamivir carboxylate hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (76)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Jun;618(7965):590-597. PMID: 37258672 -
Nat Commun
Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice. [Abstract]2026 Feb 19. PMID: 41714318 -
Nat Commun
Genotype B3.13 influenza A(H5N1) viruses isolated from dairy cattle demonstrate high virulence in laboratory models, but retain avian virus-like properties. [Abstract]2025 Jul 23;16(1):6771. PMID: 40695800 -
ACS Nano
Noninvasive visualization of respiratory viral infection using bioorthogonal conjugated near-infrared-emitting quantum dots. [Abstract]2014 Jun 24;8(6):5468-77. PMID: 24797178 -
Sci Transl Med
Baloxavir alleviates severe disease and viremia in ferrets infected with avian- or bovine-origin influenza A(H5N1) virus. [Abstract]2026 Feb 18;18(837):eadt3889. PMID: 41706870 -
Small
A Multiligand Architectural Photosensitizer That Targets Hemagglutinin on Envelope of Influenza Virus for Photodynamic Inactivation. [Abstract]2020 May;16(20):e2000556. PMID: 32329578 -
J Environ Manage
Adsorption removal of antiviral drug oseltamivir and its metabolite oseltamivir carboxylate by carbon nanotubes: Effects of carbon nanotube properties and media. [Abstract]2015 Oct 1:162:326-33. PMID: 26265601 -
Arch Pharm Res
The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. [Abstract]2018 Jun;41(6):664-676. PMID: 29572682 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Emerg Microbes Infect
Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]2025 Dec;14(1):2564308. PMID: 41069204 -
J Ethnopharmacol
Integrating bioinformatic analysis, network pharmacology, molecular docking and experimental validation to explore the mechanism of Tian Long Cha against influenza virus. [Abstract]2025 Jun 12:349:119964. PMID: 40368255 -
J Ethnopharmacol
Synergistic effects of Lianhuaqingwen in combination with Oseltamivir and Baloxavir against seasonal influenza virus: In vitro and in vivo assessment. [Abstract]2025 Feb 10;338(Pt 2):119091. PMID: 39528119 -
Talanta
Competitive ultrafiltration: A ligand-displacement strategy for rapid discovery of high-quality neuraminidase inhibitors from natural product mixtures. [Abstract]2025 Oct 2;298(Pt B):128948. PMID: 41076770 -
Eur J Med Chem
Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inhibitors. [Abstract]2023 Dec 5:261:115845. PMID: 37804770 -
Eur J Med Chem
Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. [Abstract]2021 Oct 5:221:113567. PMID: 34082224 -
Eur J Med Chem
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor. [Abstract]2020 Aug 15:200:112423. PMID: 32512482 -
Eur J Med Chem
Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors. [Abstract]2017 Dec 1:141:648-656. PMID: 29107426 -
Anal Chim Acta
Machine learning-assisted affinity ultrafiltration for bioactive natural products discovery:Application to screening of neuraminidase inhibitors from medicinal herbs. [Abstract]2025 Nov 8:1374:344522. PMID: 40983409 -
Int J Mol Sci
Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition. [Abstract]2019 Dec 12;20(24):6261. PMID: 31842256 -
BMC Microbiol
2025 May 15;25(1):292. PMID: 40375181 -
Eur J Pharm Sci
2020 Jan 15:142:105143. PMID: 31726091 -
Molecules
Synthesis and Biological Evaluation of NH2-Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors. [Abstract]2019 Jun 10;24(11):2176. PMID: 31185617 -
Eur J Pharm Sci
Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans. [Abstract]2018 Jan 1:111:167-176. PMID: 28966098 -
Molecules
Neuraminidase Inhibitory Activity and Constituent Characterization of Fagopyrum dibotrys. [Abstract]2017 Nov 18;22(11):1998. PMID: 29156573 -
Molecules
Anti-Influenza Virus Activity and Constituents. Characterization of Paeonia delavayi Extracts. [Abstract]2016 Aug 26;21(9):1133. PMID: 27571059 -
Eur J Pharm Sci
Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. [Abstract]2015 Oct 12:78:47-53. PMID: 26164127 -
Sci Rep
Potential antiviral activity of rhamnocitrin against influenza virus H3N2 by inhibiting cGAS/STING pathway in vitro. [Abstract]2024 Nov 16;14(1):28287. PMID: 39550441 -
Virol Sin
Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo. [Abstract]2021 Jun;36(3):490-500. PMID: 33044658 -
RSC Med Chem
Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase. [Abstract]2020 Jan 22;11(1):148-154. PMID: 33479615 -
Antiviral Res
High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay. [Abstract]2025 Aug:240:106209. PMID: 40484321 -
Antiviral Res
Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models. [Abstract]2025 Jul:239:106174. PMID: 40324597 -
Antiviral Res
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors. [Abstract]2024 Sep:229:105959. PMID: 38986873 -
Antiviral Res
Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. [Abstract]2022 Jun;202:105325. PMID: 35460703 -
Antiviral Res
2020 Oct:182:104886. PMID: 32750468 -
Antiviral Res
Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy. [Abstract]2020 Apr;176:104751. PMID: 32088248 -
Antiviral Res
Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro. [Abstract]2017 Jul:143:106-112. PMID: 28232246 -
Antiviral Res
Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity. [Abstract]2016 May:129:81-92. PMID: 26923882
Oseltamivir acid hydrochloride purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2016 May:129:81-92. [Abstract]
MDCK cells are infected with K435E or H274Y in the absence of compounds and maintained at 35 °C in agarose with or without 10 nM Oseltamivir or 20 μg/mL D35, respectively.
-
Antiviral Res
Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase. [Abstract]2016 Mar:127:68-78. PMID: 26802558 -
Antiviral Res
Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein. [Abstract]2014 Nov:111:69-77. PMID: 25234090
Oseltamivir acid hydrochloride purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2014 Nov:111:69-77. [Abstract]
Plaque formation of different recombinant viruses in the presence of oseltamivir. MDCK cells are infected with recombinant viruses in the absence of Oseltamivir or DS and maintained in agarose overlay medium with 50 nM Oseltamivir or 100 μg/mL DS (DS), or without compounds (None) at 35 °C.
-
Antimicrob Agents Chemother
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]2020 Jun 23;64(7):e00222-20. PMID: 32312780 -
Antimicrob Agents Chemother
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. [Abstract]2015 Aug;59(8):4962-73. PMID: 26055368 -
J Infect Dis
Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023. [Abstract]2024 Jun 14;229(6):1830-1835. PMID: 37770028 -
Virol J
Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification. [Abstract]2025 Jun 4;22(1):181. PMID: 40468427 -
Virol J
Cirsimaritin inhibits influenza A virus replication by downregulating the NF-κB signal transduction pathway. [Abstract]2018 May 21;15(1):88. PMID: 29783993 -
Influenza Other Respir Viruses
Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies. [Abstract]2025 Oct;19(10):e70176. PMID: 41116245 -
Viruses
The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro. [Abstract]2024 Sep 14;16(9):1467. PMID: 39339943 -
Viruses
2021 Aug 11;13(8):1590. PMID: 34452455 -
Viruses
A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants. [Abstract]2020 Mar 19;12(3):337. PMID: 32204549 -
J Med Virol
Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses. [Abstract]2023 Jul;95(7):e28968. PMID: 37489704 -
J Med Virol
Establishment of a rapid ELISPOT assay for influenza virus titration and neutralizing antibody detection. [Abstract]2021 Jun;93(6):3455-3464. PMID: 32621615 -
-
Peptides
Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion. [Abstract]2019 Feb:112:14-22. PMID: 30447229 -
Animal Model Exp Med
2025 Jan 26. PMID: 39865580 -
SLAS Discov
2024 Jan;29(1):66-76. PMID: 37925159 -
PLoS One
High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity. [Abstract]2016 May 27;11(5):e0156400. PMID: 27232333
Oseltamivir acid hydrochloride purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 May 27;11(5):e0156400. [Abstract]
Live-cell fluorescence imaging of infected cells of Oseltamivir-resistant virus. MDCK cells are infected with Oseltamivir-resistant 738 and -sensitive 838. After incubation at 37°C for 12 hr, the cells are incubated with BTP3-Neu5Ac with or without Oseltamivir or Zanamivir (each 100 nM for final concentrations) in an SFM at 37°C for 10 min. Fluorescent images of the cells are observed under UV irradiation by using a fluorescence microscope. A scale bar indicates 200 μm.
-
PLoS One
2014 Oct 21;9(10):e110631. PMID: 25333287 -
FEBS Open Bio
Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases. [Abstract]2013 Oct 29:3:484-9. PMID: 24265981 -
Virology
The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo. [Abstract]2025 Oct:611:110642. PMID: 40730007 -
Virology
Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. [Abstract]2020 Jun:545:1-9. PMID: 32174453 -
J Nat Med
Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. [Abstract]2019 Jun;73(3):487-496. PMID: 30758716 -
Arch Virol
2024 May 28;169(6):130. PMID: 38807015 -
Arch Virol
Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. [Abstract]2014 Dec;159(12):3269-78. PMID: 25078390 -
Biomed Chromatogr
The exploration of neuraminidase inhibitory activity on Fallopia denticulata, an ethnic herb in China. [Abstract]2021 Apr;35(4):e5024. PMID: 33169405 -
Biosci Biotechnol Biochem
Orientin suppresses oxidized low-density lipoproteins induced inflammation and oxidative stress of macrophages in atherosclerosis. [Abstract]2020 Apr;84(4):774-779. PMID: 31829093 -
-
-
-
bioRxiv
Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice. [Abstract]2024 May 8:2024.05.06.592815. PMID: 38765999 -
-
-
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299 -
-
Biomed Pharmacother
Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs. [Abstract]2018 Jan:97:385-394. PMID: 29091888
Oseltamivir acid hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Jan:97:385-394. [Abstract]
The inhibitory effects of OA on M1 protein synthesis and in three different infection protocols. M1 protein expression in H1N1-infected MDCK cells analyzed by Western blot 24 h post infection.
-
Biomed Pharmacother
Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism. [Abstract]2017 Sep:93:636-645. PMID: 28688289 -
Oncotarget
Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function. [Abstract]2017 Sep 15;8(47):83142-83154. PMID: 29137330 -
Evid Based Complement Alternat Med
The inhibitory effect of kakkonto, Japanese traditional (kampo) medicine, on brain penetration of oseltamivir carboxylate in mice with reduced blood-brain barrier function. [Abstract]2015:2015:917670. PMID: 25788966
Solvent & Solubility
DMSO : 50 mg/mL (155.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (77.93 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.90 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.90 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.1171 mL | 15.5855 mL | 31.1711 mL | 77.9277 mL |
| 5 mM | 0.6234 mL | 3.1171 mL | 6.2342 mL | 15.5855 mL | |
| 10 mM | 0.3117 mL | 1.5586 mL | 3.1171 mL | 7.7928 mL | |
| 15 mM | 0.2078 mL | 1.0390 mL | 2.0781 mL | 5.1952 mL | |
| 20 mM | 0.1559 mL | 0.7793 mL | 1.5586 mL | 3.8964 mL | |
| 25 mM | 0.1247 mL | 0.6234 mL | 1.2468 mL | 3.1171 mL | |
| 30 mM | 0.1039 mL | 0.5195 mL | 1.0390 mL | 2.5976 mL | |
| 40 mM | 0.0779 mL | 0.3896 mL | 0.7793 mL | 1.9482 mL | |
| 50 mM | 0.0623 mL | 0.3117 mL | 0.6234 mL | 1.5586 mL | |
| 60 mM | 0.0520 mL | 0.2598 mL | 0.5195 mL | 1.2988 mL | |
| DMSO | 80 mM | 0.0390 mL | 0.1948 mL | 0.3896 mL | 0.9741 mL |
| 100 mM | 0.0312 mL | 0.1559 mL | 0.3117 mL | 0.7793 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Oseltamivir acid hydrochloride Related Classifications
HY-13318A Related Classifications
Powered by Bioz